Temozolomide as Maintenance Therapy Following Induction Chemotherapy in Extensive Stage Small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2018-01-01
Target enrollment:
Participant gender:
Summary
Temozolomide may delay progression in sequence with chemotherapy. This open-label,
randomized,multicenter phase II trial was designed to evaluate the role of Temozolomide
following 4 or 6 cycles of platinum-based first-line chemotherapy in patients with newly
diagnosed estensive-stage SCLC.